Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) does not currently plan to hold an advisory committee meeting to discuss the company’s New Drug Application (NDA) for brensocatib, a treatment for patients with non-cystic fibrosis bronchiectasis. The FDA had previously granted priority review to the NDA and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act.

source: Insmed Incorporated, form 8-K filing, February 24, 2025.